ストックスクリーナーアプリを入手
1.36
6.25%
0.08
アフターアワーズ：
1.38
0.02
+1.47%
前日終値:
$1.28
開ける：
$1.22
24時間の取引高:
1.26M
Relative Volume:
5.04
時価総額：
$31.45M
収益：
-
当期純損益:
$-13.76M
株価収益率:
-1.0543
EPS:
-1.29
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+58.14%
1か月 パフォーマンス:
+37.36%
6か月 パフォーマンス:
+51.11%
1年 パフォーマンス:
+74.34%
1日の値動き範囲:
$1.22
$1.42
1週間の範囲:
$0.81
$1.42
52週間の値動き範囲:
$0.512
$2.33
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
NRSN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.36 | 31.45M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurosense Therapeutics Ltd (NRSN) 最新ニュース
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results - citybiz
NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position - TipRanks
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) - Aktiellt
NeuroSense Therapeutics Regains Nasdaq Compliance - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Hold” Rating from Maxim Group - Defense World
Maxim cuts NeuroSense shares rating to hold on capital concerns By Investing.com - Investing.com South Africa
Maxim cuts NeuroSense shares rating to hold on capital concerns - Investing.com
Comparing Emmaus Life Sciences (OTCMKTS:EMMA) & NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense aligns with FDA on Phase 3 ALS drug study By Investing.com - Investing.com Australia
NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment - TipRanks
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Desig - GuruFocus.com
NeuroSense aligns with FDA on Phase 3 ALS drug study - Investing.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - Marketscreener.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC (PR Newswire) - Aktiellt
Dewpoint Therapeutics and Mitsubishi Tanabe partner on ALS therapy - European Biotechnology News
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - The Malaysian Reserve
NeuroSense Announces Completion of PARADIGM Study Highlighting P - GuruFocus.com
NeuroSense’s PrimeC Shows Promise in ALS Treatment - TipRanks
NeuroSense Therapeutics Ltd. announced that it expects to receive $5 million in funding - Marketscreener.com
NeuroSense Therapeutics Ltd. Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - Marketscreener.com
NeuroSense secures $5 million in private placement funds By Investing.com - Investing.com Nigeria
NeuroSense Therapeutics Announces Securities Purchase Agreement - TipRanks
NeuroSense Therapeutics Announces $5 Million Private Placement - citybiz
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price - Lelezard
NeuroSense secures $5 million in private placement funds - Investing.com India
NeuroSense Therapeutics Plans to File for Early Commercializatio - GuruFocus.com
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Tr - GuruFocus.com
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstr - GuruFocus.com
NeuroSense Advances Plans for Early Commercialization of Groundb - GuruFocus.com
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS, MND - Marketscreener.com
NeuroSense Therapeutics Ltd. announced that it expects to receive $30 million in funding - Marketscreener.com
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - PR Newswire
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS i - GuruFocus.com
NeuroSense Therapeutics Secures Continued Nasdaq Listing - TipRanks
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com
NeuroSense Moves Toward Early Commercialization Of ALS Treatment In Canada, Eyeing $100M+ Market - MSN
Neurosense Therapeutics Secures $30 Million Equity Deal - TipRanks
NeuroSense Therapeutics Announces Private Placement with Senior - GuruFocus.com
NeuroSense Completes Key ALS Trial Phase - TipRanks
NeuroSense Therapeutics : INFORMATION CONTAINED IN THIS REPORT ON FORM 6 K Form 6 K - Marketscreener.com
NeuroSense schedules FDA meeting for ALS drug trial - Investing.com India
NeuroSense Therapeutics Advances ALS Drug Development Plans - TipRanks
NeuroSense schedules FDA meeting for ALS drug trial By Investing.com - Investing.com Australia
NeuroSense Therapeutics : Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission Form 6 K - Marketscreener.com
NeuroSense Therapeutics Ltd. Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - Marketscreener.com
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - Nasdaq
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission - Benzinga
NRSNNeuroSense Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
NeuroSense’s PrimeC Shows Potential in ALS Treatment - TipRanks
NeuroSense Therapeutics : New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Form 6 K - Marketscreener.com
Neurosense Therapeutics Ltd (NRSN) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):